Quris-AI Acquires Nortis (Numa Biosciences) Assets
October 29, 2024
Quris-AI has acquired the assets of Nortis (formerly Numa Biosciences) to integrate Nortis's Kidney-on-Chip microphysiology systems into Quris-AI's Bio-AI clinical prediction platform. The acquisition will combine Nortis's validated in-vitro kidney models with Quris-AI's machine-learning models and expand access to publicly funded MPS data while continuing collaborations with research institutes, the FDA and pharmaceutical partners.
- Buyers
- Quris-AI
- Targets
- Nortis (formerly Numa Biosciences, Inc.)
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Somatus Acquires Strategic Assets from Lumiata
April 28, 2022
Healthcare Services
Somatus has acquired strategic assets from Lumiata to integrate Lumiata's healthcare AI and predictive analytics into Somatus' RenalIQ platform, improving early identification of people with chronic kidney disease and prediction of disease progression. The deal brings Lumiata talent (including Jessica McCarthy) into Somatus and aims to strengthen care delivery, reduce costs for provider and health-plan partners, and address health inequities.
-
Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.
January 29, 2021
Biotechnology
Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.
-
Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences
January 18, 2024
Medical Devices
Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
Curi Bio Acquires South Korea-based Quvit Bio
January 12, 2026
Biotechnology
Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.
-
Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences
March 25, 2024
Biotechnology
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.